Send us a text
In this episode of On The Pen: The Weekly Dose, host Dave Knapp dives into the latest updates in obesity medicine, with insightful takes on current treatment breakthroughs, new medication approvals, and tips on navigating healthcare options. This week’s deep dive also touches on emerging trends in GLP-1 therapy and how recent shifts may impact accessibility for patients. Whether you’re just starting your journey or a long-time follower of GLP-1 news, this episode brings you the essentials.
Maritide Bone Density Loss:
https://www.statnews.com/2024/11/12/amgen-maritide-obesity-drug-candidate-data/
Catalent Novo Merger:
https://www.biospace.com/deals/lilly-vs-novo-the-he-said-she-said-row-about-catalents-glp-1-work
Novo War On Compounds:
https://www.onthepen.com/post/shocking-truth-about-semaglutide-what-novo-nordisk-doesn-t-want-you-to-know
Drug Shortage Policy Reform Request (VOTE!):
https://forum.policiesforpeople.com/t/compound-tirzepatide-and-semaglutide-transparency-in-fda-drug-shortage-process-503b-protection/7821
ro.co/OTP
Support the show
Our Book Has Been Released!
Decoding GLP-1: A Guide for Friends and Family of Those On The Pen
Buy Here: https://amzn.to/3Dc66d4
DNF10 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP
USE CODE "OTP10" to save 10%. A small commission is paid back to support On The Pen!
MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT:
Venmo: OnThePen
Ca$h App: ManOnMounjaro
BECOME A MEMBER:
https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join
👉 My Amazon Affiliate Store:
https://www.amazon.com/shop/manonthemounjaroonthepen
MORE COMMUNITY!
📺 Watch Our Weekly Live Show: onthepen.tv
🆕 Discord: https://discord.gg/u4Ea8qqP
🤝 Visit Our Sponsor!
GLP-1 Ro Body Plan: https://www.ro.co/otp
Report The Shortage: https://www.ro.co/supply-tracker
Does your insurance cover GLPs? https://www.ro.com/checker
📲 Contact Me: [email protected]
Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and...